home / stock / algs / algs news

ALGS News and Press, Aligos Therapeutics Inc. From 07/01/22

Stock Information
Company Name: Aligos Therapeutics Inc.
Stock Symbol: ALGS
Market: NASDAQ
Website: aligos.com
Menu
ALGS ALGS Quote ALGS Short ALGS News ALGS Articles ALGS Message Board
Get ALGS Alerts

News, Short Squeeze, Breakout and More Instantly...
ALGS - Tracking Baker Brothers Portfolio - Q1 2022 Update

Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...
ALGS - Aligos Therapeutics Presents 28-Day Safety, Efficacy and Pharmacokinetic Clinical Data for CAM Drug Candidate ALG-000184, First Clinical Data for NASH Drug Candidate ALG-055009 and Nonclinical Data in Other Chronic Hepatitis B Programs at the Europea

- Similar significant reductions of hepatitis B virus (HBV) DNA and HBV RNA observed following 28 days of daily oral ALG-000184 dosing, regardless of HBeAg status, across first four dosing chronic hepatitis B (CHB) patient cohorts -In the first clinical data presentation from our NA...

ALGS - Aligos Therapeutics to Participate in Metropolitan AntiViral Drug Accelerator, Recipient of NIH and NIAID Grant to Develop Therapeutics Against Coronaviruses and Pathogens of Pandemic Potential

SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company will part...

ALGS - Aligos Therapeutics to Present at the Jefferies 2022 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M. Blatt, Ph....
ALGS - Shopify, Lloyds Banking Group, Datadog among premarket losers' pack

Casa Systems (CASA) -18% on Q1 earnings release. Sally Beauty Holdings (SBH) -16% on Q2 earnings release. BRF (BRFS) -15% on Q1 earnings release. MaxLinear (MXL) -13% after MaxLinear confirms deal to purchase Silicon Motion for $3.8 billion. Shopif...

ALGS - Aligos Therapeutics GAAP EPS of -$0.84, revenue of $2.57M

Aligos Therapeutics press release (NASDAQ:ALGS): Q1 GAAP EPS of -$0.84. Revenue of $2.57M (+182.4% Y/Y). Cash, cash equivalents and marketable securities totaled $183.2 million as of March 31, 2022, compared with $205.8 million as of December 31, 2021. We continue to believe our cash balance ...

ALGS - Aligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business progress and...
ALGS - Aligos Therapeutics to Present 28-Day Safety, Efficacy and Pharmacokinetic Data for CAM Drug Candidate ALG-000184 and Nonclinical Data for Two Additional Chronic Hepatitis B Programs at the European Association for the Study of the Liver's International L

SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company will prese...

ALGS - Aligos Therapeutics to Announce First Quarter 2022 Results May 4, 2022

SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the c...

ALGS - Aligos to advance development of oral drug candidate ALG-097558 for COVID-19

Aligos Therapeutics (NASDAQ:ALGS +7.0%) said it had selected oral protease inhibitor ALG-097558 as its drug candidate for the treatment and prevention of COVID-19. The company said its drug ALG-097558 has shown superior potency compared to nirmatrelvir (PF-07321332) against SARS-CoV...
Previous 10 Next 10